168 related articles for article (PubMed ID: 32441887)
1. Lestaurtinib potentiates TRAIL-induced apoptosis in glioma via CHOP-dependent DR5 induction.
Cao Y; Kong S; Xin Y; Meng Y; Shang S; Qi Y
J Cell Mol Med; 2020 Jul; 24(14):7829-7840. PubMed ID: 32441887
[TBL] [Abstract][Full Text] [Related]
2. Amiodarone sensitizes human glioma cells but not astrocytes to TRAIL-induced apoptosis via CHOP-mediated DR5 upregulation.
Kim IY; Kang YJ; Yoon MJ; Kim EH; Kim SU; Kwon TK; Kim IA; Choi KS
Neuro Oncol; 2011 Mar; 13(3):267-79. PubMed ID: 21292685
[TBL] [Abstract][Full Text] [Related]
3. Arsenic trioxide sensitizes human glioma cells, but not normal astrocytes, to TRAIL-induced apoptosis via CCAAT/enhancer-binding protein homologous protein-dependent DR5 up-regulation.
Kim EH; Yoon MJ; Kim SU; Kwon TK; Sohn S; Choi KS
Cancer Res; 2008 Jan; 68(1):266-75. PubMed ID: 18172319
[TBL] [Abstract][Full Text] [Related]
4. Verrucarin A sensitizes TRAIL-induced apoptosis via the upregulation of DR5 in an eIF2α/CHOP-dependent manner.
Moon DO; Asami Y; Long H; Jang JH; Bae EY; Kim BY; Choi YH; Kang CH; Ahn JS; Kim GY
Toxicol In Vitro; 2013 Feb; 27(1):257-63. PubMed ID: 22982206
[TBL] [Abstract][Full Text] [Related]
5. Vernodalol enhances TRAIL-induced apoptosis in diffuse large B-cell lymphoma cells.
Wu W; Yang Y; Deng G; Ma L; Wei G; Zheng G; Han X; He D; Zhao Y; He J; Cai Z; Yu R
Mol Carcinog; 2017 Oct; 56(10):2190-2199. PubMed ID: 28467689
[TBL] [Abstract][Full Text] [Related]
6. Upregulation of DR5 by proteasome inhibitors potently sensitizes glioma cells to TRAIL-induced apoptosis.
Hetschko H; Voss V; Seifert V; Prehn JH; Kögel D
FEBS J; 2008 Apr; 275(8):1925-36. PubMed ID: 18341587
[TBL] [Abstract][Full Text] [Related]
7. Tanshinone IIA Facilitates TRAIL Sensitization by Up-regulating DR5 through the ROS-JNK-CHOP Signaling Axis in Human Ovarian Carcinoma Cell Lines.
Chang CC; Kuan CP; Lin JY; Lai JS; Ho TF
Chem Res Toxicol; 2015 Aug; 28(8):1574-83. PubMed ID: 26203587
[TBL] [Abstract][Full Text] [Related]
8. Apigenin potentiates TRAIL therapy of non-small cell lung cancer via upregulating DR4/DR5 expression in a p53-dependent manner.
Chen M; Wang X; Zha D; Cai F; Zhang W; He Y; Huang Q; Zhuang H; Hua ZC
Sci Rep; 2016 Oct; 6():35468. PubMed ID: 27752089
[TBL] [Abstract][Full Text] [Related]
9. Azadirone, a limonoid tetranortriterpene, induces death receptors and sensitizes human cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) through a p53 protein-independent mechanism: evidence for the role of the ROS-ERK-CHOP-death receptor pathway.
Gupta SC; Francis SK; Nair MS; Mo YY; Aggarwal BB
J Biol Chem; 2013 Nov; 288(45):32343-32356. PubMed ID: 24078627
[TBL] [Abstract][Full Text] [Related]
10. Capsaicin sensitizes malignant glioma cells to TRAIL-mediated apoptosis via DR5 upregulation and survivin downregulation.
Kim JY; Kim EH; Kim SU; Kwon TK; Choi KS
Carcinogenesis; 2010 Mar; 31(3):367-75. PubMed ID: 19939880
[TBL] [Abstract][Full Text] [Related]
11. Silibinin sensitizes human glioma cells to TRAIL-mediated apoptosis via DR5 up-regulation and down-regulation of c-FLIP and survivin.
Son YG; Kim EH; Kim JY; Kim SU; Kwon TK; Yoon AR; Yun CO; Choi KS
Cancer Res; 2007 Sep; 67(17):8274-84. PubMed ID: 17804742
[TBL] [Abstract][Full Text] [Related]
12. Cyproterone acetate enhances TRAIL-induced androgen-independent prostate cancer cell apoptosis via up-regulation of death receptor 5.
Chen L; Wolff DW; Xie Y; Lin MF; Tu Y
BMC Cancer; 2017 Mar; 17(1):179. PubMed ID: 28270124
[TBL] [Abstract][Full Text] [Related]
13. Paxilline enhances TRAIL-mediated apoptosis of glioma cells via modulation of c-FLIP, survivin and DR5.
Kang YJ; Kim IY; Kim EH; Yoon MJ; Kim SU; Kwon TK; Choi KS
Exp Mol Med; 2011 Jan; 43(1):24-34. PubMed ID: 21150246
[TBL] [Abstract][Full Text] [Related]
14. CAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction is a major component of SHetA2-induced apoptosis in lung cancer cells.
Lin YD; Chen S; Yue P; Zou W; Benbrook DM; Liu S; Le TC; Berlin KD; Khuri FR; Sun SY
Cancer Res; 2008 Jul; 68(13):5335-44. PubMed ID: 18593935
[TBL] [Abstract][Full Text] [Related]
15. Quercetin enhances apoptotic effect of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in ovarian cancer cells through reactive oxygen species (ROS) mediated CCAAT enhancer-binding protein homologous protein (CHOP)-death receptor 5 pathway.
Yi L; Zongyuan Y; Cheng G; Lingyun Z; Guilian Y; Wei G
Cancer Sci; 2014 May; 105(5):520-7. PubMed ID: 24612139
[TBL] [Abstract][Full Text] [Related]
16. Lipoxygenase inhibitor MK886 potentiates TRAIL-induced apoptosis through CHOP- and p38 MAPK-mediated up-regulation of death receptor 5 in malignant glioma.
Woo JS; Kim SM; Jeong CH; Ryu CH; Jeun SS
Biochem Biophys Res Commun; 2013 Feb; 431(2):354-9. PubMed ID: 23261452
[TBL] [Abstract][Full Text] [Related]
17. A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis.
Weinmann L; Wischhusen J; Demma MJ; Naumann U; Roth P; Dasmahapatra B; Weller M
Cell Death Differ; 2008 Apr; 15(4):718-29. PubMed ID: 18202704
[TBL] [Abstract][Full Text] [Related]
18. An Integrated Stress Response Agent that Modulates DR5-Dependent TRAIL Synergy Reduces Patient-Derived Glioma Stem Cell Viability.
Sheikh S; Saxena D; Tian X; Amirshaghaghi A; Tsourkas A; Brem S; Dorsey JF
Mol Cancer Res; 2019 May; 17(5):1102-1114. PubMed ID: 30642878
[TBL] [Abstract][Full Text] [Related]
19. Baicalein overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance via two different cell-specific pathways in cancer cells but not in normal cells.
Taniguchi H; Yoshida T; Horinaka M; Yasuda T; Goda AE; Konishi M; Wakada M; Kataoka K; Yoshikawa T; Sakai T
Cancer Res; 2008 Nov; 68(21):8918-27. PubMed ID: 18974136
[TBL] [Abstract][Full Text] [Related]
20. YM155 sensitizes triple-negative breast cancer to membrane-bound TRAIL through p38 MAPK- and CHOP-mediated DR5 upregulation.
Pennati M; Sbarra S; De Cesare M; Lopergolo A; Locatelli SL; Campi E; Daidone MG; Carlo-Stella C; Gianni AM; Zaffaroni N
Int J Cancer; 2015 Jan; 136(2):299-309. PubMed ID: 24866585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
